ArticleFrontiers in pharmacology2025
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Review
- Research Progress of Injectable Hydrogels Targeting Specific Pathogenesis for Osteonecrosis of the Femoral Head.International journal of nanomedicine · 2026Review
- The role of post-translational modifications in osteonecrosis of the femoral head.Frontiers in cell and developmental biology · 2026Review
- Icariin: from preclinical promise to clinical reality-a critical evidence-based assessment.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Icariin (ICA) has showed the beneficial effects on preventing the occurrence of steroid-induced osteonecrosis of the femoral head (SONFH) through enhancing bone formation and remodeling. In addition, the glucocorticoid-induced inhibition of cell proliferation and apoptosis are closely related to the pathogenesis of SONFH. In view of this, the present study was first designed to observe the effect of ICA on dexamethasone (Dex)-induced BMSCs and further reveal the relevant molecular mechanism. Furthermore, due to that the traditional oral administration of ICA is difficult to be absorbed and has a low bioavailability, the sustained-release ICA delivery system co-loaded thermosensitive PLGA-PEG-PLGA hydrogels was constructed, and the efficiency of this drug delivery system for the treatment of early SONFH was evaluated in rats model. Methods: The anti-apoptotic effect of ICA on the Dex-induced BMSCs was observed by crystal violet staining assay, Hoechst 33342 staining and flow cytometry analysis. Meanwhile, the protein expression levels of Akt/Bad/Bcl-2 signaling pathway were detected by Western blotting. Moreover, the sustained-release ICA delivery system co-loaded thermosensitive PLGA-PEG-PLGA hydrogels was constructed, and the sol-gel transition, Results: ICA could rescue BMSCs from Dex-induced apoptosis through promoting the phosphorylation of Akt/Bad/Bcl-2 signaling pathway. Furthermore, the degradation of copolymer was related to the ICA concentration, and the sustained-release effect of this delivery system Conclusion: Our data showed that local injection of this sustained-release drug delivery system combined with CD could significantly relieve the glucocorticoid-induced early osteonecrosis in the rats model with SONFH by increasing the residence time of ICA in the necrotic area of femoral head to maximize the anti-apoptotic, pro-osteogenic and anti-adipogenic effects of ICA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.